Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
January 21, 2024 8:50 PM 2 min read

Apple's Move To Remove Blood Oxygen Feature In US Watches May Affect Sleep Apnea Detection, Says Mark Gurman

by Ananya Gairola Benzinga Staff Writer
Follow

ArticleFeaturedTickersList12345!!!

Apple Inc. (NASDAQ:AAPL) has halted the sale of smartwatches that come with blood oxygen tracking. However, this move could reportedly influence the company’s future healthcare ventures, said Mark Gurman, in the latest installment of his weekly newsletter "Power On."

What Happened: Apple’s decision followed a federal appeals court’s denial of a request for an extended halt on the International Trade Commission ban. Faced with the alternatives of either pulling the watch off the market or disabling the feature, Apple chose the latter for its U.S. clientele.

This marks the first instance of a firm successfully persuading the ITC to ban an Apple product in the US, compelling the company to eliminate a feature.

The ongoing patent dispute casts a shadow over Apple’s future health capabilities. 

Last year, Gurman reported that sleep apnea detection, requiring dependable blood oxygen data, was among the significant new health features expected in 2024. 

"Everything I know about determining sleep apnea suggests that getting solid blood oxygen data through the night is critical for an accurate result. So the battle over the sensor probably casts doubt on that too — at least, for now," said Gurman. 

See Also: Here's How To Get Up To $349 In Apple's iPhone 7 ‘Loop Disease' Class Action Lawsuit Settlement

Why It Matters: Apple's move to dodge the import ban on Apple Watch Series 9 and Apple Watch Ultra 2  has sparked criticism from the head of Masimo Corp. (NASDAQ:MASI), the firm that initiated the patent infringement lawsuit against Apple. 

In an interview earlier this week, Masimo Corp.’s CEO Joe Kiani expressed his belief that Apple Watch users are better off without the blood oxygen monitoring feature. Kiani argued that the feature was unreliable on Apple’s latest smartwatches due to the ongoing patent dispute.

“Apple is masquerading what they are offering to consumers as a reliable, medical pulse oximeter, even though it is not,” he said, adding, “I really feel wholeheartedly that consumers are better off without it.”

Photo courtesy: Apple

Check out more of Benzinga's Consumer Tech coverage by following this link.

Read Next: Apple Watch Series 9 Vs. Series 8: Here’s An In-Depth Comparision Of Price, Power And Performance

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
NewsTechMediaApple WatchAppleversebenzinga neuroConsumer Tech
MASI Logo
MASIMasimo Corp
$137.67-%
Overview
AAPL Logo
AAPLApple Inc
$256.790.14%
MASI Logo
MASIMasimo Corp
$137.67-%
Overview
AAPL Logo
AAPLApple Inc
$256.790.14%
Comments
Loading...